1
|
Patinote C, Deleuze-Masquéfa C, Kaddour KH, Vincent LA, Larive R, Zghaib Z, Guichou JF, Assaf MD, Cuq P, Bonnet PA. Imidazo[1,2-a]quinoxalines for melanoma treatment with original mechanism of action. Eur J Med Chem 2020; 212:113031. [PMID: 33309473 DOI: 10.1016/j.ejmech.2020.113031] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2020] [Revised: 11/05/2020] [Accepted: 11/14/2020] [Indexed: 10/22/2022]
Abstract
The malignant transformation of melanocytes causes several thousand deaths each year, making melanoma an important public health concern. Melanoma is the most aggressive skin cancer, which incidence has regularly increased over the past decades. We described here the preparation of new compounds based on the 1-(3,4-dihydroxyphenyl)imidazo[1,2-a]quinoxaline structure. Different positions of the quinoxaline moiety were screened to introduce novel substituents in order to study their influence on the biological activity. Several alkylamino or alkyloxy groups were also considered to replace the methylamine of our first generation of Imiqualines. Imidazo[1,2-a]pyrazine derivatives were also designed as potential minimal structure. The investigation on A375 melanoma cells displayed interesting in vitro low nanomolar cytotoxic activity. Among them, 9d (EAPB02303) is particularly remarkable since it is 20 times more potent than vemurafenib, the reference clinical therapy used on BRAF mutant melanoma. Contrary to the first generation, EAPB02303 does not inhibit tubulin polymerization, as confirmed by an in vitro assay and a molecular modelisation study. The mechanism of action for EAPB02303 highlighted by a transcriptomic analysis is clearly different from a panel of 12 well-known anticancer drugs. In vivoEAPB02303 treatment reduced tumor size and weight of the A375 human melanoma xenografts in a dose-dependent manner, correlated with a low mitotic index but not with necrosis.
Collapse
Affiliation(s)
- Cindy Patinote
- Institut des Biomolécules Max Mousseron (IBMM), UMR 5247, CNRS, Université de Montpellier, Faculté de Pharmacie, 15 avenue Charles Flahault, BP 14491, 34093, Montpellier Cedex 5, France; Société d'Accélération du Transfert de Technologies (SATT AxLR), CSU, 950 rue Saint Priest, 34090, Montpellier, France
| | - Carine Deleuze-Masquéfa
- Institut des Biomolécules Max Mousseron (IBMM), UMR 5247, CNRS, Université de Montpellier, Faculté de Pharmacie, 15 avenue Charles Flahault, BP 14491, 34093, Montpellier Cedex 5, France.
| | - Kamel Hadj Kaddour
- Institut des Biomolécules Max Mousseron (IBMM), UMR 5247, CNRS, Université de Montpellier, Faculté de Pharmacie, 15 avenue Charles Flahault, BP 14491, 34093, Montpellier Cedex 5, France
| | - Laure-Anaïs Vincent
- Institut des Biomolécules Max Mousseron (IBMM), UMR 5247, CNRS, Université de Montpellier, Faculté de Pharmacie, 15 avenue Charles Flahault, BP 14491, 34093, Montpellier Cedex 5, France
| | - Romain Larive
- Institut des Biomolécules Max Mousseron (IBMM), UMR 5247, CNRS, Université de Montpellier, Faculté de Pharmacie, 15 avenue Charles Flahault, BP 14491, 34093, Montpellier Cedex 5, France
| | - Zahraa Zghaib
- Institut des Biomolécules Max Mousseron (IBMM), UMR 5247, CNRS, Université de Montpellier, Faculté de Pharmacie, 15 avenue Charles Flahault, BP 14491, 34093, Montpellier Cedex 5, France; Tumorigenèse et Pharmacologie Antitumorale, Lebanese University, EDST, BP 90656, Fanar Jdeideh, Lebanon
| | - Jean-François Guichou
- CNRS, UMR 5048, INSERM, U105, Université de Montpellier, Centre de Biochimie Structurale, 34090, Montpellier, France
| | - Mona Diab Assaf
- Tumorigenèse et Pharmacologie Antitumorale, Lebanese University, EDST, BP 90656, Fanar Jdeideh, Lebanon
| | - Pierre Cuq
- Institut des Biomolécules Max Mousseron (IBMM), UMR 5247, CNRS, Université de Montpellier, Faculté de Pharmacie, 15 avenue Charles Flahault, BP 14491, 34093, Montpellier Cedex 5, France
| | - Pierre-Antoine Bonnet
- Institut des Biomolécules Max Mousseron (IBMM), UMR 5247, CNRS, Université de Montpellier, Faculté de Pharmacie, 15 avenue Charles Flahault, BP 14491, 34093, Montpellier Cedex 5, France
| |
Collapse
|
2
|
Salah M, Abdelsamie AS, Frotscher M. Inhibitors of 17β-hydroxysteroid dehydrogenase type 1, 2 and 14: Structures, biological activities and future challenges. Mol Cell Endocrinol 2019; 489:66-81. [PMID: 30336189 DOI: 10.1016/j.mce.2018.10.001] [Citation(s) in RCA: 20] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/09/2018] [Revised: 08/27/2018] [Accepted: 10/04/2018] [Indexed: 12/16/2022]
Abstract
During the past 25 years, the modulation of estrogen action by inhibition of 17β-hydroxysteroid dehydrogenase types 1 and 2 (17β-HSD1 and 17β-HSD2), respectively, has been pursued intensively. In the search for novel treatment options for estrogen-dependent diseases (EDD) and in order to explore estrogenic signaling pathways, a large number of steroidal and nonsteroidal inhibitors of these enzymes has been described in the literature. The present review gives a survey on the development of inhibitor classes as well as the structural formulas and biological properties of their most interesting representatives. In addition, rationally designed dual inhibitors of both 17β-HSD1 and steroid sulfatase (STS) as well as the first inhibitors of 17β-HSD14 are covered.
Collapse
Affiliation(s)
- Mohamed Salah
- Pharmaceutical and Medicinal Chemistry, Saarland University, Campus C23, D-66123, Saarbrücken, Germany
| | - Ahmed S Abdelsamie
- Department of Drug Design and Optimization, Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Campus E81, 66123, Saarbrücken, Germany; Chemistry of Natural and Microbial Products Department, National Research Centre, Dokki, 12622, Cairo, Egypt
| | - Martin Frotscher
- Pharmaceutical and Medicinal Chemistry, Saarland University, Campus C23, D-66123, Saarbrücken, Germany.
| |
Collapse
|
3
|
Siebenbuerger L, Hernandez-Olmos V, Abdelsamie AS, Frotscher M, van Koppen CJ, Marchais-Oberwinkler S, Scheuer C, Laschke MW, Menger MD, Boerger C, Hartmann RW. Highly Potent 17β-HSD2 Inhibitors with a Promising Pharmacokinetic Profile for Targeted Osteoporosis Therapy. J Med Chem 2018; 61:10724-10738. [PMID: 30480443 DOI: 10.1021/acs.jmedchem.8b01373] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Intracellular elevation of E2 levels in bone by inhibition of 17β hydroxysteroid dehydrogenase type 2 (17β-HSD2) without affecting systemic E2 levels is an attractive approach for a targeted therapy against osteoporosis, a disease which is characterized by loss of bone mineral density. Previously identified inhibitor A shows high potency on human and mouse 17β-HSD2, but poor pharmacokinetic properties when applied perorally in mice. A combinatorial chemistry approach was utilized to synthesize truncated derivatives of A, leading to highly potent compounds with activities in the low nanomolar to picomolar range. Compound 33, comparable to A in terms of inhibitor potency against both human and mouse enzymes, displays high in vitro metabolic stability in human and mouse liver S9 fraction as well as low toxicity and moderate hepatic CYP inhibition. Thus, compound 33 showed a highly improved peroral pharmacokinetic profile in comparison to A, making 33 a promising candidate for further development.
Collapse
Affiliation(s)
| | - Victor Hernandez-Olmos
- Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Branch for Translational Medicine and Pharmacology TMP , Theodor-Stern-Kai 7 , 60596 Frankfurt am Main , Germany
| | - Ahmed S Abdelsamie
- Chemistry of Natural and Microbial Products Department , National Research Centre , Dokki, 12622 Cairo , Egypt.,Department of Pharmacy , Saarland University , Campus C2.3 , 66123 Saarbrücken , Germany
| | - Martin Frotscher
- Department of Pharmacy , Saarland University , Campus C2.3 , 66123 Saarbrücken , Germany
| | | | | | - Claudia Scheuer
- Institute for Clinical and Experimental Surgery , Saarland University , 66421 Homburg/Saar , Germany
| | - Matthias W Laschke
- Institute for Clinical and Experimental Surgery , Saarland University , 66421 Homburg/Saar , Germany
| | - Michael D Menger
- Institute for Clinical and Experimental Surgery , Saarland University , 66421 Homburg/Saar , Germany
| | - Carsten Boerger
- PharmBioTec GmbH , Science Park 1 , 66123 Saarbrücken , Germany
| | - Rolf W Hartmann
- Department of Pharmacy , Saarland University , Campus C2.3 , 66123 Saarbrücken , Germany.,Department of Drug Design and Optimization , Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) , Campus E8.1 , 66123 Saarbrücken , Germany
| |
Collapse
|
4
|
Singh P, Peddinti RK. Metal-Free Alkyl(Aryl) Transfer-Aromatization-Alkylation Domino Approach: Facile Synthesis of Branched Hydroquinones from p
-Quinols and Diaryl Carbinols. ChemistrySelect 2017. [DOI: 10.1002/slct.201700445] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Affiliation(s)
- Pallavi Singh
- Department of Chemistry; Indian Institute of Technology Roorkee; Roorkee- 247667, Uttarakhand India
| | - Rama Krishna Peddinti
- Department of Chemistry; Indian Institute of Technology Roorkee; Roorkee- 247667, Uttarakhand India
| |
Collapse
|
5
|
Bruneau-Voisine A, Wang D, Dorcet V, Roisnel T, Darcel C, Sortais JB. Mono-N-methylation of anilines with methanol catalyzed by a manganese pincer-complex. J Catal 2017. [DOI: 10.1016/j.jcat.2017.01.004] [Citation(s) in RCA: 133] [Impact Index Per Article: 19.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
|
6
|
Braun F, Bertoletti N, Möller G, Adamski J, Steinmetzer T, Salah M, Abdelsamie AS, van Koppen CJ, Heine A, Klebe G, Marchais-Oberwinkler S. First Structure–Activity Relationship of 17β-Hydroxysteroid Dehydrogenase Type 14 Nonsteroidal Inhibitors and Crystal Structures in Complex with the Enzyme. J Med Chem 2016; 59:10719-10737. [DOI: 10.1021/acs.jmedchem.6b01436] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Affiliation(s)
- Florian Braun
- Institute
for Pharmaceutical Chemistry, Philipps University Marburg, Marbacher Weg 6, 35032 Marburg, Germany
| | - Nicole Bertoletti
- Institute
for Pharmaceutical Chemistry, Philipps University Marburg, Marbacher Weg 6, 35032 Marburg, Germany
| | - Gabriele Möller
- Genome
Analysis Center, Institute of Experimental Genetics, German Research
Center for Environmental Health, Helmholtz Zentrum München, 85764 Neuherberg, Germany
| | - Jerzy Adamski
- Genome
Analysis Center, Institute of Experimental Genetics, German Research
Center for Environmental Health, Helmholtz Zentrum München, 85764 Neuherberg, Germany
- Chair
of Experimental Genetics, Technical University Munich, 85350 Freising-Weihenstephan, Germany
- German Center for Diabetes Research (DZD), 85764 Neuherberg, Germany
| | - Torsten Steinmetzer
- Institute
for Pharmaceutical Chemistry, Philipps University Marburg, Marbacher Weg 6, 35032 Marburg, Germany
| | - Mohamed Salah
- ElexoPharm GmbH, Campus A1.2, 66123 Saarbrücken, Germany
| | | | | | - Andreas Heine
- Institute
for Pharmaceutical Chemistry, Philipps University Marburg, Marbacher Weg 6, 35032 Marburg, Germany
| | - Gerhard Klebe
- Institute
for Pharmaceutical Chemistry, Philipps University Marburg, Marbacher Weg 6, 35032 Marburg, Germany
| | | |
Collapse
|
7
|
Type 2 17-β hydroxysteroid dehydrogenase as a novel target for the treatment of osteoporosis. Future Med Chem 2016; 7:1431-56. [PMID: 26230882 DOI: 10.4155/fmc.15.74] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
Abstract
Low estradiol level in postmenopausal women is implicated in osteoporosis, which occurs because of the high bone resorption rate. Estrogen formation is controlled by 17-β hydroxysteroid dehydrogenase 17-β HSD enzymes, where 17-β HSD type 1 contributes in the formation of estradiol, while type 2 catalyzes its catabolism. Inhibiting 17-β HSD2 can help in increasing estradiol concentration. Several promising 17-β HSD2 inhibitors that can act at low nanomolar range have been identified. However, there are some specific challenges associated with the application of these compounds. Our review provides an up-to-date summary of the current status and recent progress in the production of 17-β HSD2 inhibitors as well as the future challenges in their clinical application.
Collapse
|
8
|
Chen CL, Lee CC, Liu FL, Chen TC, Ahmed Ali AA, Chang DM, Huang HS. Design, synthesis and SARs of novel salicylanilides as potent inhibitors of RANKL-induced osteoclastogenesis and bone resorption. Eur J Med Chem 2016; 117:70-84. [PMID: 27089213 DOI: 10.1016/j.ejmech.2016.04.007] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2016] [Revised: 04/02/2016] [Accepted: 04/04/2016] [Indexed: 01/28/2023]
Abstract
Inhibiting osteoclastogenesis is a promising therapeutic target for treating osteoclast-related diseases. Herein, we synthesized a series of modified salicylanilides and their corresponding 3-phenyl-2H-benzo[e][1,3]oxazine-2,4(3H)-dione and 10-phenyldibenzo[b,f][1,4]oxazepin-11(10H)-one derivatives, and investigated the effects of such compounds on RANKL-induced osteoclast formation. Among them, a salicylanilide derivative (A04) and its 3-phenyl-2H-benzo[e][1,3]oxazine-2,4(3H)-dione derivative (B04) markedly suppressed RANKL-induced osteoclast differentiation and showed no significant cytotoxic effects at doses higher than that required to inhibit osteoclast formation. Both compounds reduced osteoclast formation and bone resorptive activity of osteoclasts in a dose-dependent manner. Further, the anti-osteoclastogenic effects of A04 and B04 may operate through reducing the RANKL-induced nuclear translocation of NFATc1. Accordingly, we present the potent anti-osteoclastogenic compounds A04 and B04 as promising candidates for further optimization as anti-resorptive agents.
Collapse
Affiliation(s)
- Chun-Liang Chen
- Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 110, Taiwan, ROC; School of Pharmacy, National Defense Medical Center, Taipei 114, Taiwan, ROC
| | - Chia-Chung Lee
- Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 110, Taiwan, ROC; School of Pharmacy, National Defense Medical Center, Taipei 114, Taiwan, ROC
| | - Fei-Lan Liu
- Rheumatology/Immunology/Allergy, Taipei Veterans General Hospital, Taipei 112, Taiwan, ROC
| | - Tsung-Chih Chen
- Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 110, Taiwan, ROC; School of Pharmacy, National Defense Medical Center, Taipei 114, Taiwan, ROC
| | - Ahmed Atef Ahmed Ali
- Graduate Institute of Life Sciences, National Defense Medical Center, Taipei 114, Taiwan, ROC; Taiwan International Graduate Program, Molecular and Cell Biology Program, Institute of Molecular Biology, Academia Sinica, Taipei 115, Taiwan, ROC
| | - Deh-Ming Chang
- Rheumatology/Immunology/Allergy, Taipei Veterans General Hospital, Taipei 112, Taiwan, ROC; Graduate Institute of Life Sciences, National Defense Medical Center, Taipei 114, Taiwan, ROC.
| | - Hsu-Shan Huang
- Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 110, Taiwan, ROC; School of Pharmacy, National Defense Medical Center, Taipei 114, Taiwan, ROC; Graduate Institute of Life Sciences, National Defense Medical Center, Taipei 114, Taiwan, ROC.
| |
Collapse
|
9
|
Gargano EM, Perspicace E, Carotti A, Marchais-Oberwinkler S, Hartmann RW. Addressing cytotoxicity of 1,4-biphenyl amide derivatives: Discovery of new potent and selective 17β-hydroxysteroid dehydrogenase type 2 inhibitors. Bioorg Med Chem Lett 2016; 26:21-4. [DOI: 10.1016/j.bmcl.2015.11.047] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2015] [Revised: 11/10/2015] [Accepted: 11/14/2015] [Indexed: 01/31/2023]
|
10
|
Gargano EM, Allegretta G, Perspicace E, Carotti A, Van Koppen C, Frotscher M, Marchais-Oberwinkler S, Hartmann RW. 17β-Hydroxysteroid Dehydrogenase Type 2 Inhibition: Discovery of Selective and Metabolically Stable Compounds Inhibiting Both the Human Enzyme and Its Murine Ortholog. PLoS One 2015; 10:e0134754. [PMID: 26230928 PMCID: PMC4521925 DOI: 10.1371/journal.pone.0134754] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2015] [Accepted: 07/13/2015] [Indexed: 11/19/2022] Open
Abstract
Design and synthesis of a new class of inhibitors for the treatment of osteoporosis and its comparative h17β-HSD2 and m17β-HSD2 SAR study are described. 17a is the first compound to show strong inhibition of both h17β-HSD2 and m17β-HSD2, intracellular activity, metabolic stability, selectivity toward h17β-HSD1, m17β-HSD1 and estrogen receptors α and β as well as appropriate physicochemical properties for oral bioavailability. These properties make it eligible for pre-clinical animal studies, prior to human studies.
Collapse
Affiliation(s)
- Emanuele M. Gargano
- Pharmaceutical and Medicinal Chemistry, Saarland University, Saarbrücken, Germany
| | - Giuseppe Allegretta
- Helmholtz Institute for Pharmaceutical Research Saarland, Saarbrücken, Germany
| | - Enrico Perspicace
- Pharmaceutical and Medicinal Chemistry, Saarland University, Saarbrücken, Germany
| | - Angelo Carotti
- Dipartimento Farmaco-Chimico, Università degli Studi di Bari, Bari, Italy
| | | | - Martin Frotscher
- Pharmaceutical and Medicinal Chemistry, Saarland University, Saarbrücken, Germany
| | - Sandrine Marchais-Oberwinkler
- Pharmaceutical and Medicinal Chemistry, Saarland University, Saarbrücken, Germany
- Helmholtz Institute for Pharmaceutical Research Saarland, Saarbrücken, Germany
- * E-mail: (RWH); (SMO)
| | - Rolf W. Hartmann
- Pharmaceutical and Medicinal Chemistry, Saarland University, Saarbrücken, Germany
- Helmholtz Institute for Pharmaceutical Research Saarland, Saarbrücken, Germany
- * E-mail: (RWH); (SMO)
| |
Collapse
|
11
|
Gargano EM, Perspicace E, Hanke N, Carotti A, Marchais-Oberwinkler S, Hartmann RW. Metabolic stability optimization and metabolite identification of 2,5-thiophene amide 17β-hydroxysteroid dehydrogenase type 2 inhibitors. Eur J Med Chem 2014; 87:203-19. [DOI: 10.1016/j.ejmech.2014.09.061] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2014] [Revised: 09/16/2014] [Accepted: 09/18/2014] [Indexed: 12/26/2022]
|
12
|
Novel, potent and selective 17β-hydroxysteroid dehydrogenase type 2 inhibitors as potential therapeutics for osteoporosis with dual human and mouse activities. Eur J Med Chem 2014; 83:317-37. [DOI: 10.1016/j.ejmech.2014.06.036] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2014] [Revised: 06/12/2014] [Accepted: 06/17/2014] [Indexed: 11/19/2022]
|
13
|
Zhang X, Wang F, Qi Z, Yu S, Li X. Rhodium(III)-Catalyzed Redox-Neutral C–H Arylation via Rearomatization. Org Lett 2014; 16:1586-9. [DOI: 10.1021/ol500186j] [Citation(s) in RCA: 46] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Affiliation(s)
- Xueyun Zhang
- Dalian
Institute of Chemical Physics, Chinese Academy of Sciences, Dalian 116023, China
- School
of Chemistry and Pharmaceutial Engineering, Qilu University of Technology, Ji’nan 250353, China
| | - Fen Wang
- Dalian
Institute of Chemical Physics, Chinese Academy of Sciences, Dalian 116023, China
| | - Zisong Qi
- Dalian
Institute of Chemical Physics, Chinese Academy of Sciences, Dalian 116023, China
| | - Songjie Yu
- Dalian
Institute of Chemical Physics, Chinese Academy of Sciences, Dalian 116023, China
| | - Xingwei Li
- Dalian
Institute of Chemical Physics, Chinese Academy of Sciences, Dalian 116023, China
| |
Collapse
|